Lecia V Sequist
Overview
Explore the profile of Lecia V Sequist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
264
Citations
31879
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider J, Kurmi K, Dai Y, Dhiman I, Joshi S, Gassaway B, et al.
Cell
. 2025 Feb;
188(5):1248-1264.e23.
PMID: 39919745
Little is known about metabolic vulnerabilities in oncogene-driven lung cancer. Here, we perform a phosphoproteomic screen in anaplastic lymphoma kinase (ALK)-rearranged ("ALK+") patient-derived cell lines and identify guanylate kinase 1...
2.
Mishra A, Huang S, Dubash T, Burr R, Edd J, Wittner B, et al.
Nat Commun
. 2025 Jan;
16(1):32.
PMID: 39746954
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we...
3.
Dagogo-Jack I, Cooper A, Johnson B, Gainor J, Lin J, Sequist L, et al.
Lung Cancer
. 2024 Nov;
199:108003.
PMID: 39615410
Introduction: Anaplastic lymphoma kinase rearranged (ALK + ) lung cancers often develop ALK-independent resistance mechanisms that reactivate the mitogen-activated protein kinase pathway signaling pathway. We therefore evaluated alectinib combined with...
4.
Keane F, Yeap B, Khandekar M, Lin J, Dagogo-Jack I, Sequist L, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(4):975-979.
PMID: 39577475
Purpose: The role of stereotactic body radiation therapy (SBRT) in the management of advanced EGFR/ALK/ROS1-driven non-small cell lung carcinoma (NSCLC) remains undefined. In EGFR-mutant NSCLC, 50-60% of recurrences on first-line...
5.
Simon J, Mikhael P, Graur A, Chang A, Skates S, Osarogiagbon R, et al.
Invest Radiol
. 2024 Oct;
PMID: 39437009
Purpose: Sybil is a validated publicly available deep learning-based algorithm that can accurately predict lung cancer risk from a single low-dose computed tomography (LDCT) scan. We aimed to study the...
6.
Burr R, Leshchiner I, Costantino C, Blohmer M, Sundaresan T, Cha J, et al.
Nat Cancer
. 2024 Oct;
5(11):1681-1696.
PMID: 39406916
Although the development of multiple primary tumors in smokers with lung cancer can be attributed to carcinogen-induced field cancerization, the occurrence of multiple tumors at presentation in individuals with EGFR-mutant...
7.
Felip E, Metro G, Soo R, Wolf J, Solomon B, Tan D, et al.
Eur J Cancer
. 2024 Jul;
208:114182.
PMID: 38986421
Purpose: This phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). Methods: In phase 1b, patients with...
8.
Mazzone P, Bach P, Carey J, Schonewolf C, Bognar K, Ahluwalia M, et al.
Cancer Discov
. 2024 Jun;
14(11):2224-2242.
PMID: 38829053
Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung...
9.
Chang A, Piper-Vallillo A, Mak R, Lanuti M, Muzikansky A, Rotow J, et al.
Oncologist
. 2024 May;
29(7):609-618.
PMID: 38761385
Background: The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non-small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with...
10.
Chang A, Potter A, Yang C, Sequist L
Hematol Oncol Clin North Am
. 2024 May;
38(4):755-770.
PMID: 38724286
Recent advances in lung cancer treatment have led to dramatic improvements in 5-year survival rates. And yet, lung cancer remains the leading cause of cancer-related mortality, in large part, because...